MedTrace Logo

Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

NCT02111499 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-06-09

No results posted yet for this study

Summary

Clinical investigation of anti-psoriatic efficacy and atrophy

Conditions

Interventions

DRUG

LAS41004-IMP1

daily topical application

DRUG

LAS41004 IMP2

daily topical application

DRUG

LAS41004 IMP3

daily topical application

DRUG

LAS41004 IMP4

daily topical application

DRUG

LAS41004 IMP6

daily topical application

DRUG

LAS41004 IMP5

once daily, topical

Sponsors & Collaborators

  • proDERM GmbH

    collaborator INDUSTRY

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Kirstin Deuble-Bente, Dr med · proDERM GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-05-31
Completion
2014-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02111499 on ClinicalTrials.gov